Clinical trial
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 27, 2023
- Completion date
- March 24, 2028
- Enrollment
- 943 (actual)
- Sites
- 311
Conditions
As the registry lists them; a condition with its own page is linked.